
浏览全部资源
扫码关注微信
四川大学 华西第二医院 出生缺陷与相关妇儿疾病教育部重点实验室,成都 610041
黄佳,硕士,医师,从事儿童肾病的临床诊疗工作,E-mail:13281105689@163.com
王峥,博士,主任医师,从事儿童肾病的临床诊疗工作,E-mail:wangzhenghuaxifuer@163.com
收稿日期:2020-10-09,
网络出版日期:2020-11-05,
纸质出版日期:2021-05-20
移动端阅览
黄佳,王峥.知柏地黄丸合五苓散加减辅助治疗儿童难治性肾病综合征的临床疗效[J].中国实验方剂学杂志,2021,27(10):70-75.
HUANG Jia,WANG Zheng.Clinical Efficacy on Addition and Subtraction Therapy of Zhibai Dihuangwan Combined with Wulingsan on Children with Refractory Nephrotic Syndrome[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(10):70-75.
黄佳,王峥.知柏地黄丸合五苓散加减辅助治疗儿童难治性肾病综合征的临床疗效[J].中国实验方剂学杂志,2021,27(10):70-75. DOI: 10.13422/j.cnki.syfjx.20210134.
HUANG Jia,WANG Zheng.Clinical Efficacy on Addition and Subtraction Therapy of Zhibai Dihuangwan Combined with Wulingsan on Children with Refractory Nephrotic Syndrome[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(10):70-75. DOI: 10.13422/j.cnki.syfjx.20210134.
目的
2
探讨知柏地黄丸合五苓散加减辅助治疗难治性肾病综合征(RNS)患儿肝肾阴虚证的临床疗效及对免疫炎症反应的调节作用。
方法
2
将108 例RNS患儿按照随机数字表法分为观察组和对照组各54例。两组均给予醋酸泼尼松片联合他克莫司胶囊的基础治疗。对照组口服六味地黄口服液,5~10 mL/次,2次/d;观察组内服知柏地黄丸合五苓散加减,1剂/d。两组患儿均连续治疗6个月。比较治疗前后24 h尿蛋白定量(24 h-UTP),血清白蛋白(ALB),血肌酐(Scr),尿素氮(BUN),总胆固醇(TC),甘油三脂(TG),低密度脂蛋白(LDL),高密度脂蛋白(HDL),肝肾阴虚证评分、纤维蛋白原(FIB),
D
-二聚体(
D
-D),凝血酶原时间(PT)和活化部分凝血活酶时间(APTT);检测治疗前后肿瘤坏死因子-
α
(TNF-
α
),白细胞介素(IL)-6,IL-10和IL-17,CD4
+
和CD8
+
,辅助性T细胞17(Th17),调节性T细胞(Treg),并计算CD4
+
/CD8
+
和Th17/Treg。
结果
2
观察组患儿24 h-UTP水低于对照组,ALB水平高于对照组(
P
<
0.01);观察组患儿TC,TG,LDL均低于对照组(
P
<
0.01),HDL高于对照组(
P
<
0.01);观察组患儿FIB和
D
-D均低于对照组(
P
<
0.01),观察组患儿TNF-
α
,IL-10,IL-6和IL-17均低于对照组(
P
<
0.01);观察组患儿CD4
+
,Treg和CD4
+
/CD8
+
均高于对照组(
P
<
0.05),CD8
+
,Th17和Th17/Treg均低于对照组(
P
<
0.05);观察组综合疗效高于对照组(
Z
=2.02,
P
<
0.05),观察组中医证候疗效高于对照组(
Z
=2.10,
P
<
0.05)。
结论
2
在激素联合他克莫司治疗的基础上,知柏地黄丸合五苓散加减辅助治疗RNS肝肾阴虚证患儿可减轻尿蛋白,改善脂代谢紊乱和高凝状态,并能调节免疫炎症反应,综合疗效和中医证候疗效。
Objective
2
This study aims to investigate the clinical effect of addition and subtraction therapy of Zhibai Dihuangwan combined with Wulingsan in the treatment of refractory nephrotic syndrome (RNS) with Yin deficiency of liver and kidney and its regulatory effect on immune inflammatory response.
Method
2
In this study, 108 children were randomly divided into observation group (54 cases) and control group (54 cases). Patients in two groups were treated with prednisone acetate tablets combined with tacrolimus capsules . Patients in control group took Liuwei Dihuang oral liquid, 5-10 mL/time, twice a day. Patients in control group were prescribed the addition and subtraction therapy of Zhibai Dihuangwan combined with Wulingsan, 1 dose/day. The course of treatment for both groups was 6 months. The 24 h urine total protein (24 h-UTP), serum albumin (ALB), serum creatinine (Scr), blood urea nitrogen (BUN), total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL), high density lipoprotein (HDL), liver and kidney Yin deficiency syndrome score, fibrinogen (FIB),
D
-dimer (
D
-D), prothrombin time (PT) and activated partial thromboplastin time (APTT) were compared before and after treatment. Also, tumor necrosis factor-
α
(TNF-
α
), interleukin-6(IL-6), IL-10, IL-17, CD4
+
and CD8
+
, helper T lymphocytes17 (Th17), regulatory T cell (Treg) were detected before and after treatment, and CD4
+
/CD8
+
and
Th17/Treg were also calculated.
Result
2
The levels of 24 h-UTP, TC, TG, LDL, FIB,
D
-D, TNF-
α
, IL-10, IL-6 and IL-17 in observation group were all lower than those in control group (
P
<
0.01), and the levels of CD8
+
, Th17 and Th17/Treg were alsolower than those in control group (
P
<
0.05). While the levels of HDL,ALB, CD4
+
, Treg and CD4
+
/CD8
+
in observation group were higher than those in control group (
P
<
0.05). The comprehensive efficacy in observation group was better than that in control group (
Z
=2.02,
P
<
0.05), and the traditional Chinese medicine (TCM) syndrome efficacy of observation group was better than that of control group (
Z
=2.10,
P
<
0.05).
Conclusion
2
Based on the treatment of hormone combined with Tacrolimus, Zhibai Dihuangwan combined with Wulingsan can reduce urinary protein, improve lipid metabolism disorder and hypercoagulability, and regulate immune inflammatory reaction in patients with RNS and Yin deficiency of liver and kidney, with remarkable comprehensive effect and TCM syndrome effect.
IIJIMA K , SAKO M , NOZU K . Rituximab for nephrotic syndrome in children [J]. Clin Exp Nephrol , 2017 , 21 ( 2 ): 193 - 202 .
凌晨 , 刘小荣 . 儿童特发性肾病综合征:B细胞紊乱导致的疾病? [J]. 中华肾脏病杂志 , 2020 , 36 ( 8 ): 648 - 651 .
中华医学会儿科学分会肾脏学组 . 激素耐药型肾病综合征诊治循证指南(2016) [J]. 中华儿科杂志 , 2017 , 55 ( 11 ): 805 - 809 .
汪之玉 , 唐璟 , 熊维建 . 国医大师郑新治疗儿童难治性肾病综合征经验 [J]. 河南中医 , 2020 , 40 ( 1 ): 60 - 64 .
陈乃清 , 彭贝如 . 儿童肾病综合征中医病因病机探讨 [J]. 新中医 , 2019 , 51 ( 12 ): 320 - 322 .
金善善 , 许文成 , 王小琴 . 难治性肾病综合征的中医治疗策略 [J]. 中国中西医结合肾病杂志 , 2018 , 19 ( 12 ): 1111 - 1112 .
李佑生 , 廖水玉 , 李董平 , 等 . 知柏地黄汤对大鼠膜性肾病大剂量激素治疗中的增效减毒作用 [J]. 华东理工大学学报:自然科学版 , 2016 , 42 ( 2 ): 187 - 193 .
屠晶晶 , 郭旭 , 王帅 , 等 . 泼尼松联合知柏地黄丸治疗对肾病综合征肾功能及炎症因子水平的影响 [J]. 中国药物与临床 , 2019 , 19 ( 3 ): 355 - 357 .
栾佳 , 吕静 , 刘淼 . 五苓散治疗IgA肾病理论探讨 [J]. 辽宁中医药大学学报 , 2019 , 21 ( 3 ): 120 - 122 .
中华医学会儿科学分会肾脏病学组 . 儿童常见肾脏疾病诊治循证指南(一):激素敏感、复发/依赖肾病综合征诊治循证指南(试行) [J]. 中华儿科杂志 , 2009 , 47 ( 3 ): 167 - 170 .
中华中医学会 . 中医儿科常见病诊疗指南 [M]. 北京 : 中国中医药出版社 : 2012 : 91 - 97 .
叶任高 , 陈裕盛 , 方敬爱 . 肾脏病诊断与治疗及疗效标准专题讨论纪要 [J]. 中国中西医结合肾病杂志 , 2003 , 4 ( 6 ): 355 - 357 .
郑筱萸 . 中药新药临床研究指导原则(试行) [M]. 北京 : 中国医药科技出版社 , 2002 : 388 - 389 .
郑志方 , 陈国利 , 孙鹏 , 等 . 百令胶囊联合他克莫司治疗儿童原发性肾病综合征的疗效及安全性评价 [J]. 中华中医药学刊 , 2020 , 38 ( 5 ): 203 - 206 .
雷蕾 , 熊维建 , 杨敬 , 等 . 国医大师郑新“肾病三因论”治疗肾病综合征浅析 [J]. 中华中医药杂志 , 2020 , 35 ( 2 ): 709 - 710 .
刘海波 , 卢佩 , 李春梦 , 等 . 肾病综合征患儿凝血指标检测价值分析 [J]. 陕西医学杂志 , 2020 , 49 ( 4 ): 506 - 509 .
SINHA A , PURASWANI M , KALAIVANI M , et al . Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial [J]. Kidney Int , 2019 , 95 ( 1 ): 210 - 218 .
童科珍 , 毛建华 , 傅海东 , 等 . 肾病综合征患儿血清细胞因子水平及T细胞亚群变化的临床意义 [J]. 中华临床免疫和变态反应杂志 , 2016 , 10 ( 4 ): 351 - 356 .
BHATIA D , SINHA A , HARI P , et al . Rituximab modulates T- and B-lymphocyte subsets and urinary CD80 excretion in patients with steroid-dependent nephrotic syndrome [J]. Pediatr Res , 2018 , 84 ( 4 ): 520 - 526 .
0
浏览量
16
下载量
4
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621